Valo Health

TARA Biosystems, Inc. is a biotechnology company that specializes in developing organ-on-a-chip technology for evaluating new therapies and drug compounds, particularly in the field of cardiac medicine. Founded in 2014 and based in the United States, the company produces predictive in vitro human cardiac tissue models derived from human stem cells. These models are matured to physiologically relevant adult-like levels, allowing for accurate measurement of cardiac functionality, including contractile force. TARA Biosystems focuses on enhancing drug discovery and safety assessment processes by providing high-fidelity solutions that enable faster and safer development of new medicines. By harnessing human biology and data, the company aims to transform cardiac drug discovery and improve patient health outcomes.

Courier Therapeutics is a biotechnology company focused on advancing cancer immunotherapy through its innovative protein therapeutics platform. The company has developed a technology that enables the precise delivery of cytokines to natural killer (NK) cells and CD8 T cells, enhancing the efficacy of immunotherapies while minimizing side effects. This technology is grounded in insights gained from viral stealth proteins, which have evolved to selectively target specific receptors. In addition to its applications in cancer treatment, Courier Therapeutics' platform holds potential for addressing autoimmune and inflammatory diseases, aiming to activate the immune system effectively against a range of health challenges.

Numerate Inc., established in 2007 and headquartered in San Bruno, California, is a biotechnology company specializing in small molecule therapeutics development. It offers a drug design platform that integrates data science, machine learning, cloud-scale analytics, and medicinal chemistry to predict how potential drugs will behave in lab and body settings. This platform enables Numerate to explore vast chemical spaces efficiently, accelerating drug discovery for diseases like obesity, heart failure, Alzheimer's, and Huntington's disease. By combining computational power with traditional medicinal chemistry, Numerate aims to make the drug development process more cost-effective, faster, and successful than conventional methods.